2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term
There's a lot for investors to really like about Vertex Pharmaceuticals (NASDAQ: VRTX). The company reached profitability earlier this year. It has reported a string of positive clinical results for its cystic fibrosis drugs. And, oh yes, the stock has more than doubled so far in 2017.
Chief Commercial Officer Stuart Arbuckle answered questions at the Morgan Stanley healthcare conference on Monday, and his comments highlighted the two totally different ways investors should be looking at Vertex. Here are the fast-growing biotech's short-term and long-term challenges and opportunities.
Image source: Getty Images.
Source: Fool.com
Vertex Pharmaceuticals Inc. Stock
€461.30
1.100%
The stock is one of the favorites of our community with 55 Buy predictions and 2 Sell predictions.
On the other hand, the target price of 450 € is below the current price of 461.3 € for Vertex Pharmaceuticals Inc., so the potential is actually -2.45%.
